Data from tumors of patients enrolled in clinical trials involving treatment with immune check inhibitors confirmed high levels of PD-L1 expression in sRCC of clear-cell type, with ≥50% of patients exhibiting a PD-L1 expression ≥1% of tumor [223] or microenvironment immune-infiltrating cells [224]. Here, CD274 is linked to neoplasm.